ReGenTree Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Joint Venture
  • Financing Rounds
  • 1

ReGenTree General Information

Description

Developer of RGN-259 for ophthalmic indications. The company conducts a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK) and a 2b/3 dose-response, confirmatory trial for dry eye syndrome.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReGenTree Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ReGenTree‘s full profile, request access.

Request a free trial

ReGenTree Executive Team (1)

Name Title Board Seat Contact Info
Won Yang President & Chief Executive Officer
To view ReGenTree’s complete executive team members history, request access »

ReGenTree Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ReGenTree‘s full profile, request access.

Request a free trial